Identify tumor-reactive γδ T cells to target colonrectal cancer with TEGs

Generally CRC have a low mutational load then the patients are unreactive to the actual cancer immunotherapy with checkpoint inhibitors and CAR-T cell therapies which are dependent on the mutational load of the tumor. Our challenge is to find a treatment option for many patients suffering from cancer with a low mutational load. To do it we're focus in a subtype of T-cell: the gd T cells a subtype of T-cell which share adaptive and innate immunity features. gd T cells are able to sense the tumor in a mutational load indipendent way. Our aim is finding CRC-reactive gdTCR and use them to create a TEG therapy as promising option for CRC patients with a low mutational load.

Contact 
Lucrezia Gatti